The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 April 2026•

1 min read

Analysts Split on SLB and Pfizer as AI Growth Clashes with Healthcare Headwinds

Key Facts

1UBS reiterated a 'Buy' rating on SLB stock with a $61.00 price target, betting on digital growth and AI infrastructure.

2RBC Capital maintained an 'Underperform' rating on Pfizer with a $25.00 price target due to competitive pressures and declining Paxlovid demand.

3SLB announced a partnership with NVIDIA for AI infrastructure in the energy sector.

Create Free Account

Financial analysts have issued contrasting outlooks for energy giant SLB and pharmaceutical leader Pfizer, highlighting divergent sector trends. UBS reiterated its 'Buy' rating on SLB stock with a $61.00 price target, citing significant potential in digital expansion and AI infrastructure. The energy services firm recently bolstered its tech credentials through a strategic partnership with NVIDIA aimed at driving innovation within the sector. Conversely, RBC Capital maintained an 'Underperform' rating on Pfizer, setting a price target of $25.00 amid ongoing revenue concerns. The bearish outlook for Pfizer stems from intensified competition and a sharp decline in demand for its COVID-19 treatment, Paxlovid. While SLB leverages AI to offset regional market headwinds, Pfizer continues to struggle with product-specific challenges and post-pandemic revenue normalization.